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ABSTRACT

6-PHOSPHOFRUCTO-2-KINASE INHIBITION
INDUCES AUTOPHAGY AS A SURVIVAL
MECHANISM
Alden Klarer

May 21, 2013

Altered metabolism has long been recognized as a defining characteristic
of tumor cells. The increased glycolytic phenotype, an observation credited to
Otto Warburg in 1956, is almost universal for cancer cells, making metabolic
enzymes attractive targets for cancer therapy. However, anti-metabolic drugs,
thus far, have not lived up to expectations as stand-alone agents to treat this
disease. Unlike glycolytic enzymes that directly catabolize glucose to pyruvate,
the family of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFBs)
control the conversion of fructose-6-phosphate to and from fructose-2,6bisphosphate, a key regulator of the glycolytic enzyme phosphofructokinase-1
(PFK-1). One isoform, PFKFB3, has been shown to be highly expressed by
human cancer cells and a specific PFKFB3 small molecule inhibitor, (3-(3v

pyridinyl)-1-(4-pyridinyl)-2-propen-1-one [3PO] is currently being developed for
clinical use. However, the effectiveness of current chemotherapeutics is limited
by the development of drug resistance, which is especially problematic for antimetabolic drugs where the starvation state activates a variety of survival
mechanisms within the cell that contribute to resistance. One such mechanism
used by all cells to survive nutrient-poor conditions is the activation of autophagy,
the process of cellular self-catabolism.

Autophagic induction allows for the

continued generation of biosynthetic intermediates that can be used for energy
generation and critical metabolic processes while also ensuring prompt disposal
of damaged and malfunctioning organelles before they cause cellular harm. We
hypothesized that the functional starvation induced by inhibition of PFKFB3 in
tumor cells might induce autophagy as a pro-survival mechanism and that the
combination of drugs targeting PFKFB3 with pharmacologic inhibitors of
autophagy could increase anti-tumor effects. This hypothesis has been tested
and our data reveal that knockdown or inhibition of PFKFB3 results in autophagic
induction.

This induction appears to serve as a survival mechanism as

evidenced by furthered cell death upon the addition of inhibitors of autophagy.
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CHAPTER I

GENERAL INTRODUCTION
Cancer cells have altered cellular metabolism.
The metabolic alterations characteristic of tumor cells have now
reached hallmark status [1].

Increased glucose uptake and utilization, first

described by Warburg in 1956, provides biosynthetic precursors for these rapidly
dividing cells and also may be a means by which cancer cells compensate for
reduced ATP production [2, 3].

This counterintuitive replacement of a more

efficient system, oxidative respiration, that generates 36 mol of ATP per mol of
glucose, with glycolysis which only produces 2 ATP, to generate increased
energy needed by highly proliferative tumor cells has been rationalized by the
rapid rates at which glucose can be metabolized through glycolysis [4].

There

are a number of theories pertaining to why tumor cells take up and utilize more
glucose than normal cells.

Some have proposed that mitochondrial defects

result in the preferential use of glycolysis; however, support for this view is limited
[5-7].

Others

speculate

that

hypoxia

encountered

within

the

tumor

microenvironment due to outgrowing its blood supply, results in the shift to
glycolysis [8].

Whether due to hypoxia, or to other causes, it is clear that

changes in glucose uptake or glycolytic flux can result from changes in the
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expression or activity of a number of key proteins involved in the glycolytic
pathway including glucose transporter-1, hexokinase, pyruvate kinase, and a
family of enzymes involved in the regulation of glycolysis, the PFKFBs [9-16].

PFKFB3 can regulate glycolysis by controlling levels of F2,6BP
Bifunctional

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases

(PFKFBs) regulate glycolytic flux by controlling the steady state concentration of
fructose 2,6 bisphosphate (F2,6BP), a potent allosteric regulator of PFK-1[17].
The PFKFB family consists of 4 isoforms of which PFKFB3 is of particular
interest in tumor cells [18]. PFKFB3 mRNA and protein are increased in tumors
when compared to normal tissue [19, 20]. This increase is mediated in part
through repeating AUUUA elements in the 3’-UTR of its mRNA which are present
in the mRNAs of several proto-oncogenes and have been shown to increase
translational activity [21]. Additionally, PFKFB3 has a kinase: phosphatase ratio
of 740:1, due to the lack of regulatory residues present on other isoforms [22].
The result is a considerable increase in F2,6BP and subsequent upregulation of
glycolysis following increased PFKFB3 expression [23-25].

Knockdown of

PFKFB3 using siRNA decreases glycolysis, cell proliferation and inhibits
anchorage-independent growth, making this enzyme a promising target for anticancer therapy [26].

Despite the development of numerous anti-metabolic

agents to treat cancer, these drugs have not seen the clinical success anticipated
based on their pre-clinical profiles and their presumed tumor-specific activity.
[27-32].

Interestingly, in a clinical trial testing 2-deoxyglucose, a competitive
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inhibitor of glucose metabolism [33] in prostate cancer patients, an autophagic
resistance, indicated by decreased p62 expression, was observed in the majority
of the patients treated [34]. Recently, the combination of autophagy inhibitors
with compounds that induce metabolic stress has drawn great attention and
chloroquine, a drug that has been shown to inhibit autophagy, is now being used
alone and in combination with other chemotherapeutics in human cancer trials
[35-37]

Anti-metabolic targeting can mimic a low nutrient environment and lead to
activation of autophagy
Cells in low nutrient environments, such as those with reduced amino
acids or glucose, activate the cellular self-digestion process of autophagy [3840].

While this process occurs at a basal level within cells playing a

complementary role with the proteasome to help clear larger and more abundant
material, the induction of autophagy can be triggered by stressful stimuli such as
hypoxia or nutrient deprivation. Under these conditions, autophagy is a means
by which cells are able to degrade cellular components to provide biosynthetic
precursors which can be used for anabolic processes and energy production [4144].

Targeting cancer cell metabolism is a promising strategy for anti-tumor

therapy due to selectivity for the more metabolically active tumor cells. However,
as with many other chemotherapeutic agents, cancer cells have developed
resistance mechanisms in response to treatment with anti-metabolic drugs.
Amongst these resistance mechanisms, the induction of autophagy may play an
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especially critical role in conferring resistance to anti-metabolic drugs since they
induce states that mimic low nutrient environments that can stimulate autophagy.
For example, 2-deoxy-glucose has been shown to induce autophagy both in vitro
and in vivo as part of a phase I clinical trial for prostate cancer [34, 45, 46].

Autophagy may serve to protect cells from metabolic stress
Although autophagy has been implicated as either a mechanism for
adaptive cell survival or for cell death, the process can serve either function
depending on the stimulus, the timing, and the degree of activation. There are
numerous examples of the pro-survival role of autophagy in cells. Potentially
hazardous damaged mitochondria are routinely degraded by autophagic selfdigestion [47, 48].

Amino acids can stimulate the TCA cycle by increasing

capacity through anaplerotic reactions that produce compounds like ketoglutarate. Amino acids and fatty acids also produce acetyl-CoA which, as a
substrate for the TCA cycle, is converted to carbon dioxide and water fueling
cellular energetic processes [41-44].

Autophagy has also been shown to

promote cellular survival in tumor cells treated with chemotherapeutic agents,
e.g. etoposide, temozolomide, trastuzumab and imatinib [49-52]. Due to this
demonstrated function of autophagy in protecting cells experiencing stress, it is
reasonable to postulate that this process may protect cells that are confronted
with the starvation condition created by metabolic inhibitors.
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Co-targeting PFKFB3 and the autophagic pathway may result in increased
anti-cancer effects
Molecular modeling has allowed for the development of novel small
molecule inhibitors that are able to target PFKFB3 enzyme activity. One such
inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), has been shown to
suppress glycolysis flux to lactate, decrease glucose uptake and attenuate the
proliferation of human cancer cell lines in vitro [53]. Similar inhibition was also
observed in vivo, and, although tumor growth was decreased by treatment with
3PO, it was not completely suppressed [53]. We postulated that the metabolic
stress caused by PFKFB3 inhibition might activate autophagy as a survival
pathway that could confer resistance to 3PO. Chloroquine (CQ), an anti-malarial
agent that is relatively well tolerated and has been used in humans since the
1940’s has been shown to inhibit autophagy and potentiate cancer cell death and
is now being added to a number of other drugs as a part of several human
cancer clinical trials [54-59].

We hypothesized that the combination of the

PFKFB3 inhibitor 3PO with the autophagy inhibitor CQ might lead to a significant
improvement in anti-cancer effect of 3PO in vitro and that this combination might
also increase efficacy of 3PO as an anti-tumor agent in vivo which could have
major implications for clinical trials using PFKFB3 inhibitors.
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CHAPTER II

KNOCKDOWN OF 6-PHOSPHOFRUCTO-2-KINASE (PFKFB3) RESULTS IN
INHIBITION OF GLYCOLYSIS AND INDUCTION OF AUTOPHAGY

Introduction

Tumor cell dependence on increased glucose uptake and glycolysis
allows for the increased production of ATP, nucleic acids, amino acids and fatty
acids required for proliferation [60].

Glycolytic flux is controlled through the

irreversible, rate-limiting enzyme, PFK-1. This enzyme is allosterically inhibited
by ATP, which reduces flux when cellular ATP production exceeds utilization
[61].

When energy reserves are reduced, AMP activates PFK-1.

However,

fructose 2,6 bisphosphate (F2,6BP), is also a potent activator of PFK-1 [17]. The
family of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatases (PFKFBs) is
responsible for establishing the steady state levels of cellular F2,6BP.
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The PFKFB family consists of four members, (PFKFB1-4), which act to
regulate the concentration of F2,6BP in cells [62-64]. The PFKFB3 isoform, with
a kinase: phosphatase ratio of 740:1, due to the absence critical residues
required for regulating kinase and phosphatase activity [65] has been shown to
be expressed at higher levels in tumor cells [20]. This upregulation is mediated
in part through an AUUUA-rich region in the 3’ untranslated region of its mRNA
which controls mRNA stability and translational activity [23, 65, 66].

The

PFKFB3 isoform also contains a hypoxia responsive element making it a direct
transcriptional target of HIF-1 [22, 67-69].

Finally, PFKFB3 is activated by

mitogenic signals and is stabilized after the loss of PTEN [23, 70-75]. These
data indicate that the PFKFB3 isoform may play a role in the increased glycolytic
phenotype of tumor cells relative to normal cells, which has led to the interest in
targeting PFKFB3 as an anti-cancer strategy.

Additionally, previous studies

have shown that knockdown of PFKFB3 reduces glycolytic flux and has antiproliferative effects in tumors cells [26].
The interest in PFKFB3 as an anti-tumor target has resulted in the
development of a number of small molecule inhibitors against the enzyme [53,
76] of which some are in the process of entering Phase I clinical trials as anticancer therapeutics.
Chemotherapies, even those with extremely promising results in vitro, have
long been plagued by resistance when administered to cancer patients.
Amongst the large number of resistance mechanisms, autophagy has been
shown to be activated by a large number of chemotherapeutic agents as a pro-
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survival pathway and is now being studied as a potential target for both single
and combination cancer therapy trials [50, 52, 77, 78].
Autophagy, a term first coined by Christian de Duve in 1963 is the
evolutionarily conserved process of cellular self-catabolism [79]. Of the three
types of autophagy, macroautophagy, microautophagy, and chaperone-mediated
autophagy, macroautophagy is the most well-characterized and is referred to as
autophagy in this dissertation. Autophagy is normally active at low levels in most
cells and functions to remove long-lived proteins and organelles. This process
has also been observed to protect cells by removing intracellular pathogens,
potentially harmful damaged mitochondria and in generating metabolic
substrates during nutrient deprivation [41-44, 80]. The process of autophagy
involves the initial formation of a double-membraned vesicle, thought to originate
from de novo synthesis as well as sources of cellular membrane such as the
plasma

membrane,

the

Golgi

complex,

endoplasmic reticulum

or

the

mitochondrial membrane [81-87]. As maturation of this membrane continues,
LC3-I is modified by the addition of phosphatidylethanolamine to form LC3-II
which is incorporated into the growing membrane as a scaffolding protein [88].
Cargo is recruited to this forming autophagosome by p62, an adapter molecule
with ubiquitin-binding domains that recognize poly-ubiquitinated organelles, or
proteins [89].
degraded [89].

Ultimately, autophagosomes fuse with lysosomes where cargo is
Autophagy normally functions at basal levels in most cells can

be induced by a variety of stressful stimuli such as hypoxia or glucose
deprivation, where it is presumed to promote survival [90].
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Regulation of autophagy is mainly controlled through inhibition by the
mammalian target of rapamycin (mTOR) pathway. In response to rapamycin, a
compound isolated from soil-dwelling bacterial and originally used as an
antimicrobial agent, mTOR activity is suppressed [91]. However, mTOR is now
known to be regulated by other stimuli, especially signals associated with cellular
energy status. When nutrients are plentiful, mTOR phosphorylates and activates
ribosomal S6 kinases resulting in increased protein translation [92, 93]. At the
same time, mTOR blocks autophagy by inhibition of a critical component in the
autophagic pathway, Ulk1[94].

Upon nutrient deprivation, such as that

experienced by glucose withdrawal, the AMP:ATP ratio is altered and AMP, and
more recently revealed, ADP, binds to cellular energy sensor AMP-activated
protein kinase (AMPK) causing a conformational change that favors the
activation via phosphorylation at Thr 172 by upstream kinase LKB1 [95-98].
Upon phosphorylation, AMPK can inhibit mTOR activity by phosphorylation of
TSC2 which suppresses Rheb, an mTOR activator [99, 100]. AMPK can also
directly phosphorylate ULK1 to induce autophagy [99, 101, 102]. In this way,
nutrient deprivation can signal both the inhibition of protein translation and the
activation of the catabolic process of autophagy [103].
Previous studies have shown that loss of PFKFB3 expression or inhibition of
its enzyme activity result in decreased glucose uptake, effectively starving the
cells. Cellular responses to metabolic stress during starvation are varied and
depend on numerous factors including but not limited to; cell type, the
proliferative state of the cell and the extent and time of starvation. The induction
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of autophagy is one response mechanism that has been shown to increase cell
survival during times of metabolic stress by allowing for the production of
nutrients and sustained metabolism [41-44].
Based on the known metabolic effects of PFKFB3 targeting, we sought to
determine the effects that knockdown of PFKFB3 would have on the activation of
autophagy. In the current chapter, we find that knockdown of PFKFB3 results in
an increase in autophagy and that this increase is likely mediated through the
mTOR signaling pathway.
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Materials and Methods

Cell Culture
Human colorectal carcinoma cells (HCT116) obtained from American
Type Culture Collection (Manassas, VA) and were cultured with McCoy’s 5A
medium (Gibco, Grand Island, NY) supplemented with 10% calf serum and
50ug/mL gentamicin. Cells were incubated at 37 C with 5% CO2.

Transfection
HCT-116 cells were plated at 100,000 cells/well of a 6-well dish in 2.5 ml
complete medium. 24 h after seeding, cells were transfected with either control
siRNA (Stealth Negative Control Medium GC Duplex), or PFKFB3 siRNA
(PFKFB3HSS107860;

5’ UUCAUCAGGUAGUACACGCGGC 3’, both from

Invitrogen, Grand Island, NY). OptiMEM (Invitrogen, Grand Island, NY) with 1%
Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY) was incubated at RT for
5 minutes. siRNA was added to the Lipofectamine mixture and incubated for 20
minutes at room temperature. The mixture was added to a single well of the 6well plate for a total volume of 3 ml and a final siRNA concentration of 10nM.
Cells were incubated at 37 C for 48 hours before harvest. Samples in which
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bafilomycin A1 was used were treated with 1nM bafilomycin A1 (Sigma, St.
Louis, MO) for 24 hours prior to harvest.

Protein Extraction
Cells were washed with PBS then lifted in 0.25% Trypsin (Gibco, Grand
Island, NY) and pelleted by centrifugation. Pellets were lysed in protein lysis
buffer (Thermo, Rockford, IL) supplemented with protease and phosphatase
inhibitors (Sigma, St. Louis, MO).

Samples were homogenized by passing

repeatedly through a 28 ½ gauge needle and then incubated on ice for 20
minutes before centrifugation at 2,000 g for 5 minutes at 4 C and collection of
supernatants.

Protein concentration was determined using bicinchoninic acid

assay (Thermo, Rockford, IL).

Immunoblotting
Equal amounts of protein were added to loading buffer (BioRad, Hercules,
CA) containing 10ul/ml β mercaptoethanol and heated to 98 C for 5 minutes and
then loaded onto a 4-12% gradient SDS-polyacrylamide gel (BioRad, Hercules,
CA) and run for 60 minutes at 130 volts.

Protein was transferred to a

nitrocellulose membrane over 1 hour at 400 mA and then blocked in 5% non-fat
milk for 1 hour before incubation with primary antibodies. Antibodies against
LC3, p62, pAMPK, AMPK, p-p70S6K, p70S6K, pS6, S6 (Cell Signaling, Danvers,
MA), PFKFB3, Tel2 (Protein Tech, Chicago, IL), β actin (Sigma, St. Louis, MO)
were diluted 1:1000 and were incubated overnight at 4 C, with the exception of
12

p62 and β actin Ab that were incubated at room temperature for 1 hour.
Membranes were washed for 30 minutes in Tris-Buffered Saline with Tween-20
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) before addition of
secondary antibodies (anti-mouse or anti-rabbit, diluted 1:10,000 in TBS-T,
(Sigma, St. Louis, MO).

ECL Western Blotting Detection Kit (Amersham/GE

Pittsburgh, PA) was used to develop membranes. Quantitative densitometry was
performed using Image J (NIH).

F2,6BP Assay
Intracellular fructose 2,6 bisphosphate (F2,6BP) levels were determined
using a method previously described [104].

Briefly, HCT-116 cells were

harvested 48 hours after transfection and centrifuged at 200 x g. The pellets
were resuspended in 50mM Tris acetate (pH 8.0) and 100 mM NaOH then
incubated at 80 C for five minutes and then placed on ice.

Extracts were

neutralized to pH 7.2 with 1 M acetic acid and 1 M Hepes and then incubated at
25 C for 2 min in 50mM Tris, 2mM Mg2+, 1mM F6P, 0.15mM NAD, 10u/l PPidependent PFK1, 0.45 kU/I aldolase, 5 kU/I triosephosphate isomerase, and 1.7
kI/I glycerol-3-phosphate dehydrogenase. 0.5mM pyrophosphate was added and
the rate of change in absorbance (OD=339 nm) per min over five minutes was
determined. A calibration curve using 0.1 to 1 pmol of F2,6BP (Sigma, St. Louis,
MO) was used to calculate F2,6BP which was then normalized to total protein.
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Glucose Uptake Assay
HCT-116 cells were plated at 100,000 cells in each well of a 6-well dish.
Cells were transfected with either control siRNA or siRNA directed against
PFKFB3. 48 hours post-transfection, cells were washed with PBS and media
was replaced with glucose-free RPMI 1640 for 30 minutes. 2-[1-14C]-deoxy-Dglucose (Perkin Elmer, Waltham, MA) was added for 30 minutes. Cells were
then washed three times with ice-cold RPMI 1640 containing no glucose. Cells
were lysed with 0.1% SDS. Scintillation counts (counts/min) were measured on
a portion of lysate and normalized to protein concentration using the remainder of
the lysate. Data are represented as mean + SD from duplicate samples.

Acridine Orange Immunofluorescence
After 48 hours of transfection, HCT-116 cells were washed with PBS and
then stained with 0.01mg/ml acridine orange in PBS for 15 minutes at 37 C.
Cells were washed twice with PBS then harvested for study by microscopy or
flow cytometry.

For immunofluorescent examination and imaging, cells were

viewed using an EVOSfl fluorescent microscope (AMG, Grand Island, NY).
Acridine orange was visualized using an overlay of GFP and RFP filters. For
flow cytometry, green (510-530nm) and red (650nm) fluorescence emission from
10,000 cells illuminated with blue (488nm) excitation light was measured (BD
FACSCalibur, San Jose, CA). FlowJo software (TREE STAR Inc, San Carlos,
CA) was used to calculate the red: green fluorescence ratio.
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Electron Microscopy
HCT-116 cells were prepared for electron microscopy 48 hours posttransfection. Cells were washed twice with PBS and fixed in cold glutaraldehyde
(3% in 0.1M cacodylate buffer, pH 7.4) for 30 minutes. Samples were post fixed
in OsO4 and 100nm sections were taken and stained with uranyl/lead citrate and
viewed using a transmission electron microscope (Phillips CM12). Methodology
and identification of autophagic structures was based on established criteria and
previous studies [105-107].

ATP Determination
ATP levels were determined using a bioluminescence assay (Invitrogen,
Grand Island, NY) following established protocols from suppliers. Briefly, cells
were lysed on cultured plates using a passive lysis buffer and snap frozen in
liquid nitrogen then thawed at 37 C and spun at 1200 x g for 30 seconds and
4C to clear the lysates.
containing

reaction

Lysate was added to a prepared reaction solution

buffer,

DTT,

d-luciferin

and

firefly

luciferase

and

luminescence was read using a luminometer (Biotek, Winooski, VT). ATP was
determined based on a standard curve using 1-500nM ATP and was calculated
relative to protein concentration.

15

Results

Knockdown of PFKFB3 results in decreased glycolytic flux
In order to reduce PFKFB3 levels, a siRNA directed against PFKFB3 was
transfected into human colorectal carcinoma cells (HCT-116).

Protein

expression, assessed by Western blotting, was inhibited by >90% at 48 hours by
the PFKFB3-specific siRNA relative to cells transfected with the negative control
(p value < 0.05) (Figure 1).

After confirmation of siRNA-mediated knockdown,

the product of the enzyme, fructose 2,6 bisphosphate (F2,6BP) was measured
using an enzyme-coupled assay.

Knockdown of PFKFB3 resulted in a 60%

reduction in F2,6BP at 48 hours after transfection (p value < 0.05) (Figure 2).
Blocking the production of F2,6BP leads to reduced activity of PFK-1 [23].
Glucose uptake was used as an indirect measure of PFK-1 activity as loss of
PFK-1 activity results in the intracellular accumulation of glucose and its
derivatives reducing further glucose uptake. To measure glucose uptake 2-[114

C]-deoxy-D-glucose (2DG) was added to cells transfected with either a

negative control siRNA or a siRNA directed against PFKFB3. 2DG uptake was
reduced by more than 50% (p value < 0.05) after 48 hours in cells with reduced
PFKFB3 expression relative to the negative control (Figure 3).

16

Figure 1. Treatment of cells with siRNA directed against PFKFB3 mRNA
results in decreased steady-state levels of PFKFB3 protein. HCT-116 cells
were transfected with either a control siRNA (ctrl) or 10nM of a siRNA directed
against PFKFB3 (PFKFB3).

Total protein was harvested 48 hours post-

transfection and protein levels relative to β actin were determined by Western
blotting. Densitometry data are presented as the mean fold change + SD from
three experiments. (p value < 0.05)
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Figure 1
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Figure 2. Knockdown of PFKFB3 reduces fructose 2,6 bisphosphate
(F2,6BP) levels.

HCT-116 cells were transfected with either a control siRNA

(ctrl) or 10nM of a siRNA directed against PFKFB3 (PFKFB3).

Fructose 2,6

bisphosphate levels were determined using an enzyme-coupled assay. Data are
presented as the mean pmol/mg protein + SD from three experiments. (p value <
0.05).
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Figure 2.
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Figure 3. 2-[1-14C]-deoxy-D-glucose uptake is reduced by PFKFB3
knockdown. 48 hours after transfection with either control (ctrl) or PFKFB3specific siRNA (PFKFB3), glucose uptake was measured using 2-[1-14C]-deoxyD-glucose.

Data are presented as the mean counts + SD from three

experiments. (p value < 0.05)
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(cpm x 103/g protein)

Figure 3.
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PFKFB3 knockdown results in activation of autophagy
Glucose starvation is known to increase autophagy in a number of model
systems. Thus we sought to determine if the decrease in glucose uptake due to
knockdown of PFKFB3 similarly increased autophagy in our model system. Four
measures of autophagy were used including protein markers LC3-II and p62,
acridine orange immunofluorescence, and electron microscopy. Knockdown of
PFKFB3 resulted in an 8-fold increase in LC3-II protein levels relative to the
negative control (p value < 0.05). Addition of bafilomycin A1, a vacuolar type H+ATPase that inhibits lysosomal function, was used to block LC3-II degradation
and resulted in a further increase in LC3-II, indicating autophagic flux is
increased rather than merely a block in LC3-II degradation (Figure 4) [108, 109].
As an additional measure of autophagy, protein levels of p62, a ubiquitin-binding
scaffold protein that plays a role in targeting of cargo to autophagosomes, where
it is also degraded, was measured. Knockdown of PFKFB3 resulted in a ~90%
decrease (p value < 0.05) in p62 protein levels (Figure 4) [110].
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Figure 4. Protein markers of autophagy, LC3-II and p62, are altered after
knockdown of PFKFB3. 48 hours after transfection with either control (ctrl) or a
siRNA directed against PFKFB3 (PFKFB3), LC3-II protein levels were
determined using Western blotting. Treatment with 1nM bafilomycin A1 (Baf A1)
was used to determine if LC3-II levels were a result of increased autophagic flux
or impaired degradation. Quantitative densitometry was performed to assess
relative protein levels. LC3-II and p62 levels are expressed as the mean fold
change + SD from three experiments relative to β actin and control. (p value <
0.05)
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Figure 4.

25

As a second measure of autophagy, acridine orange immunofluorescence
was used.

Acridine orange, a cell-permeable fluorescent dye, becomes

protonated and trapped in acidic compartments such as lysosomes and, upon
excitation (488 nM), emits a red

light (650 nM).

Acridine orange

immunofluorescence was assessed by both fluorescent microscopy and by flow
cytometry. HCT-116 cells transfected with PFKFB3 siRNA had a significantly
higher emission of red light (650) when viewed by fluorescent microscopy (Figure
5A). Acridine orange fluorescence was quantified by flow cytometry. PFKFB3
knockdown resulted in a shift in FL-3 (red) fluorescence, indicating that the
PFKFB3-siRNA transfected cells had a larger quantity of acidic compartments (p
value <0.05), characteristic of cells with increased autophagic activity (Figure
5B).
Another methodology commonly used to study autophagy is electron
microscopy. HCT-116 cells were transfected with PFKFB3 siRNA or a negative
control siRNA and 48 hours post-transfection, were collected and prepared for
electron microscopy.

Sections were studied using a transmission electron

microscope (Phillips CM12).

An increased number of intracellular structures

including double-membrane bound vesicles, consistent with autophagosomes
were visualized in cells transfected with PFKFB3 siRNA [111]. Representative
images of these cells and structures were collected (Figure 6).
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Figure 5. Acridine orange immunofluorescence is increased by PFKFB3
knockdown. After 48 hours of transfection with either control (ctrl) or PFKFB3specific siRNA, cells were stained with acridine orange and observed by
fluorescent microscopy. Representative images were taken.

Cells were then

collected by flow cytometry to measure the relative content of acidic
compartments.

Data are presented as the mean percentage of cells with high

acridine orange staining + SD. (p value < 0.05)
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Figure 5.
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Figure 6. Autophagic structures are visible by electron microscopy after
knockdown of PFKFB3. 48 hours after transfection, HCT-116 were harvested
and fixed for electron microscopy. Microscopic examination of the cells treated
with

PFKFB3

siRNA

contained

intracellular

autophagosomes (arrow).
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structures

consistent

with

Figure 6.
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Autophagy due to PFKFB3 knockdown may result from mTOR inhibition
Protein collected from HCT-116 cells transfected with either a negative
control siRNA or a PFKFB3-specific siRNA for 48 hours was used for
immunoblotting to measure levels of proteins involved in the mTOR pathway.
Relative to total AMPK, pAMPK was increased after 48 hours of transfection with
PFKFB3 siRNA. AMPK activation is known to suppress mTOR activity which can
be measured using downstream mTOR effectors p70 S6 kinase (p70S6K) and
ribosomal protein S6 (S6). The phosphorylated forms of both p70S6K and S6
were decreased by PFKFB3 knockdown, relative to their total expression level
(Figure 7) indicating suppression of the mTOR pathway.

mTOR inhibition

resulting from AMPK activation can occur when the intracellular ATP is reduced
relative to AMP [112]. ATP levels after PFKFB3 knockdown were determined
using a bioluminescence assay. 48 hours post-transfection, PFKFB3 knockdown
resulted in a ~30% decrease in ATP (p value <0.05) (Figure 8). Taken together,
these data indicate that suppression of glucose uptake may result in decreased
ATP, increased AMPK activation, mTOR pathway inhibition and resultant
activation of autophagy.
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Figure 7. Protein markers downstream of mTOR are decreased by PFKFB3
knockdown. After 48 hours of transfection with either a control or a PFKFB3specific siRNA, protein expression of both phosphorylated and total levels of
downstream mTOR targets, p70S6K and ribosomal protein S6 (S6) were
measured using Western blotting. Activating phosphorylation of a well-studied
upstream inhibitor of mTOR activity, AMPK, was also measured. Quantitative
densitometry is reported as phosphorylated relative to total protein for AMPK,
p70S6K and S6 and relative to β actin for LC3. All are relative to control. Data
are presented as the mean fold change + SD of three experiments. (p value <
0.05)
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Figure 7.
-
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Figure 8. PFKFB3 knockdown reduces ATP levels.

HCT-116 cells were

transfected with either a control or a PFKFB3-specific siRNA. 48 hours after
transfection cells were harvested for ATP determination. ATP was measured
using a bioluminescence assay and data are presented as the mean + SD of
ATP relative to control from three experiments. (p value < 0.05)
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Figure 8.
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Discussion

Members of the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
(PFKFB) family have been shown to be highly expressed in neoplastic relative to
normal tissue [19, 20].

This increase in expression occurs concurrently with

increased glucose uptake and utilization by tumors.

For these reasons, the

family of PFKFBs has become an attractive target for anti-cancer drug
development. The PFKFB3 isoform is of particular interest in this pursuit due to
the considerable imbalance of this enzyme’s kinase to phosphatase activity.
Increased activity of PFKFB3 results in the production of a large amount of
F2,6BP, resulting in PFK-1 activation and increased glycolytic flux [18, 20, 26].
Inhibition of PFKFB3 has been shown to reduce glucose uptake in vitro and in
vivo. Although the precise mechanism for decreased glucose uptake is not well
defined, suppression of PFK-1 activity caused by decreased F2,6BP is expected
to increase F6P which is in equilibrium with G6P, a potent inhibitor of hexokinase
and, thus, of glucose uptake [113].

However, tumor cells are quite

heterogeneous as a result of ongoing genetic alteration such that even cells
within a single tumor can have distinctly different responses to a stimulus. For
this reason it is important to validate each model system used when studying the
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effects of genetic manipulation of a target.

To evaluate the effect of PFKFB3

knockdown, a siRNA approach was used in a transformed cell line derived from a
human colon adenocarcinoma (HCT-116). Knockdown of PFKFB3 in this cell
line resulted in a substantial reduction in PFKFB3 protein expression. At the
same time there was also a decrease in glucose uptake and in fructose 2,6
bisphosphate production as would be expected with reduced PFKFB3
expression.
The metabolic stress caused by reduced glucose availability results in a
number of cellular defense mechanisms critical to survive transitory periods of
starvation.

These include the suppression of energy-requiring processes by

reducing the expression of biosynthetic genes, inhibiting the activity of
translational machinery and halting the cell cycle [114-116]. At the same time,
catabolic processes, such as autophagy, are used to recycle intracellular
components in order to provide metabolic substrates which can then be used to
generate energy as well as to remove potentially harmful intracellular material
such as damaged mitochondria [41, 44, 117-119]. To determine if the reduced
glucose uptake due to knockdown of PFKFB3 caused cells to activate this
catabolic process, autophagy markers were assessed.
Knockdown of PFKFB3 in this model system resulted in changes in
protein markers involved in the autophagic process. There was an increase in
the lipidated form of the autophagosomal membrane protein LC3 and a decrease
in protein levels of cargo protein p62 in cells transfected with PFKFB3 siRNA.
Microtubule-associate protein 1 light chain 3-II (LC3-II) is a component of the
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autophagosomal membrane.

LC3 is cleaved to LC3-I which liberates a C-

terminal glycine that allows the conjugation to phosphatidylethanolamine (PE)
whereupon

it

can

target

the

autophagosomal

membrane.

Although

counterintuitive, the heavier LC3-II migrates faster than LC3-I due to its
hydrophobicity, and is seen as the lower band in Western blotting (Figure 4). [88,
120]. Increased LC3-II can indicate either increased autophagic synthesis or
reduced autophagic degradation. The addition of bafilomycin A1, an inhibitor of
the vacuolar type H+-ATPase, allows for the determination of autophagic flux by
inhibiting lysosomal acidification and blocking degradation of LC3-II [88, 121,
122].

The further increase in LC3-II protein observed in the presence of

bafilomycin A1 after knockdown of PFKFB3 indicates that knockdown is inducing
autophagy rather than merely causing a block in LC3-II degradation. PFKFB3
knockdown also resulted in decreased p62 protein levels. p62 is an autophagy
cargo receptor protein that contains an LC3-interacting region that targets it and
its cargo to the autophagosome.

In autophagy competent cells, this cargo

protein is degraded along with autophagosomal contents resulting in decreased
total levels [123].
Additionally, knockdown of PFKFB3 resulted in cells with a higher volume
of acidic compartments as measured using acridine orange staining, consistent
with increased autophagy. When visualized by electron microscopy, PFKFB3
knockdown also resulted in the appearance of autophagosomal structures.
Taken together, these data support the induction of autophagy due to knockdown
of PFKFB3.
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Based on these observations, it appears that cells respond to PFKFB3
knockdown by increasing autophagic processing. Protein expression suggests
that this induction is via the energy sensing AMPK/mTOR pathway based on an
increased

amount

of

phosphorylated

AMPK

and

a

decrease

in

the

phosphorylated forms of downstream mTOR effectors p70 S6 kinase and
ribosomal protein S6. However, because gene silencing is not currently a widely
used cancer therapy technique, the significance of these studies in the setting of
human disease cannot be determined using knockdown methodologies alone.
To increase its relevance most targeting is aimed at the identification of
compounds with anti-tumor efficacy. The interest in PFKFB3 as an anti-cancer
target has resulted in the identification and validation of a number of compounds
that inhibit enzyme function. In order to determine if these observations made
using genetic knockdown might result in meaningful advances in tumor therapy,
further studies were conducted using a PFKFB3 small molecule inhibitor that had
previously been shown to inhibit PFKFB3 enzyme function.
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CHAPTER III

INHIBITION OF PFKFB3 USING 3-(3-PYRIDINYL)-1-(4-PYRIDINYL)
2-PROPEN-1-ONE (3PO), RESULTS IN AUTOPHAGIC INDUCTION

Introduction

The interest in PFKFB3 as a drug target for cancer treatment has now
resulted in the identification of small molecule inhibitors of enzyme activity [53,
76].

Molecular modeling allowed for the computational screening of a large

number compounds with the potential to bind the fructose-6-phosphate binding
pocket of PFKFB3. Further validation of selected compounds resulted in the
identification of a compound with dose-dependent inhibition of PFKFB3, termed
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) (Figure 9). This compound
was shown to suppress glucose uptake and F2,6BP production and, importantly,
seemed to be cancer-specific due to the selective suppression of growth of
transformed cells relative to untransformed cells [53]. Using this inhibitor, we
were also able to show reduced glucose uptake and F2,6BP in our model
system.
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Since a reduction in PFKFB3 activity results in decreased cellular glucose
uptake, and glucose starvation is an established stimulus for increased
autophagic flux, it was hypothesized that starvation due to PFKFB3 inhibition
would increase autophagic flux. In the following results section, treatment of
transformed cells with 3PO is shown to result in increased autophagy.
Interestingly, the mechanism by which autophagy is induced following drug
treatment does not appear to be the same as that observed using siRNA
mediated knockdown.

Although PFKFB3 inhibition using 3PO results in

decreased ATP, this change does not occur until long after the effects on
metabolism.

The very early effects of 3PO on glucose uptake and F2,6BP

relative to that with siRNA-mediated knockdown pointed to another source for
autophagic induction, oxidative stress.
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Figure 9. 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was designed
to inhibit PFKFB3 activity. Computational modeling led to the identification of a
small molecule inhibitor of PFKFB3 termed -(3-pyridinyl)-1-(4-pyridinyl)-2-propen1-one (3PO) (Figure 9A).

This compound can be seen within the PFKFB3

binding pocket (Figure 9B) [53].
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Figure 9.
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Materials and Methods
Cell Culture
Cells were cultured as described in Chapter II.

Drug Treatment
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) (Advanced Cancer
Therapeutics). Samples in which bafilomycin A1 was used were treated with
1nM bafilomycin A1 (Sigma, St. Louis, MO) 24 hours prior to harvest.

Protein Extraction and Immunoblotting
Protein extraction and Western blotting were performed as described in
Chapter II.

F2,6BP Assay
Intracellular fructose 2,6 bisphosphate (F2,6BP) levels were measured
after two or eight hours of drug treatment as described in Chapter II.
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Glucose Uptake Assay
Glucose uptake after two or eight hours of treatment was measured using
2-[1-14C]-deoxy-D-glucose as described in Chapter II.

Acridine Orange Immunofluorescence
Acridine orange staining and detection was determined as described in
Chapter II.

Electron Microscopy
HCT-116 cells were prepared for electron microscopy 24 hours after drug
treatment as described in Chapter II.

ATP Determination
ATP levels were determined after 6, 12 or 24 hours of treatment as
described in Chapter II.

Glutathione Measurement
GSH-Glo Glutathione Assay (Promega) was used to measure total glutathione
levels following manufacturer’s protocol. Briefly, cells were lifted and washed in
PBS. 10,000 cells from each sample were added each well of an opaque 96-well
plate. Cells were lysed with passive lysis buffer containing luciferin-NT (+ NEM
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for the measurement of GSSG). Luciferin generation reagent containing DTT,
glutathione-S-transferase and glutathione reaction buffer was added and the
plate was incubated at room temperature for 30 minutes. Luciferin detection
reagent was added and plate was read using a luminescence reader after 15
minute incubation at room temperature. Glutathione was calculated based on a
standard curve generated using 0.25 to 16 M GSH.

Reactive Oxygen Species Flow Cytometry
1nM 2’,7’ –dichlorofluorescein diacetate (DCFDA) (Molecular Probes) was
diluted in 1X PBS containing magnesium and calcium (Gibco) and added to
washed cells and incubated at 37C for 30 minutes before being analyzed by a
flow cytometry (BD FACSCalibur, San Jose, CA).

Data was analyzed using

FlowJo software (TREE STAR Inc, San Carlos, CA). Results were calculated as
average of triplicate samples + SD.

Flow Cytometry for Cell Death
Cells were stained with annexin-V labeled with FITC and propidium iodide
following manufacturer’s protocol (BD Biosciences). Briefly, cells were lifted and
pelleted by centrifugation at 2,500 rpm for 5 minutes. Cell pellets were washed
with 1X PBS and 100,000 cells were pelleted by centrifugation at 2,500 rpm for 5
minutes.

Pellets were resuspended in 1X Binding Buffer and Annexin-V/FITC

and/or Propidium Iodide was added and cells were incubated in the dark at room
temperature for 10 minutes. 1X Binding Buffer was added to increase volume
46

and 10,000 events were counted for each sample using the appropriate filters for
FITC and PI detection (BD FACSCalibur, San Jose, CA). Data was analyzed
using FlowJo software (TREE STAR Inc, San Carlos, CA).
calculated as average of triplicate samples + SD.
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Results were

Results

Small molecule inhibition of PFKFB3 decreases glucose uptake
A small molecule designed to target the fructose-6-phosphate binding site
of the PFKFB3 enzyme has previously been shown to suppress glycolysis, inhibit
recombinant PFKFB3 activity, and decrease glucose uptake and fructose
2,6,bisphosphate (Figure 9).

This inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-

propen-1-one (3PO), has also been used as an anti-tumor agent in vivo. To
validate this small molecule in our model system HCT-116 cells were treated and
fructose 2,6 bisphosphate levels and glucose uptake were measured. HCT-116
cells were treated with either vehicle alone or 10 M 3PO.

Fructose 2,6

bisphosphate was measured using an enzyme-coupled reaction and a sharp
~50% drop in fructose 2,6 bisphosphate was noted only 2 hours after drug
treatment (Figure 10). 3PO-treated cells were also assessed for glucose uptake
using 2-[1-14C]-deoxy-D-glucose. Relative to vehicle treated cells, ~35% reduced
glucose uptake was observed in 3PO treated cells as early as two hours after
drug treatment (Figure 11).
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Figure 10. Small molecule inhibition of PFKFB3 reduces fructose
2,6,bisphosphate (F2,6BP) levels.

To determine the activity of 3PO in the

current model system, HCT-116 cells were treated with 10 M 3PO and cells
were harvested to measure fructose 2,6 bisphosphate using an enzyme coupled
assay.

Data are presented as the mean pmol/mg protein + SD from three

experiments. (p value < 0.05)
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Figure 10.

+ 3PO (10 M)
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Figure 11. A small molecule inhibitor of PFKFB3, 3PO, reduces 2-[1-14C]deoxy-D-glucose uptake. 2-[1-14C]-deoxy-D-glucose uptake was measured in
HCT-116 cells treated with either vehicle or 10 M 3PO. Data are presented as
the mean counts + SD from three experiments. (p value < 0.05)
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Figure 11.

+ 3PO (10 M)
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Inhibition of PFKFB3 induces autophagy
Multiple markers of autophagy were measured following small molecule
inhibition of PFKFB3. Treatment of HCT-116 cells with 7.5, 10, or 15 M 3PO for
24 hours led to the increased expression of protein marker LC3-II in a dose
dependent manner. Like PFKFB3 knockdown, the LC3-II induction by 3PO is
likely due to increased synthesis rather than a blockade of protein degradation as
indicated by the further increase in LC3-II upon addition of bafilomycin A1 (Figure
12). 3PO also resulted in a decreased amount of p62 (Figure 12).
Treatment with 7.5, 10, or 15 M 3PO for 24 hours increased acridine
orange immunofluorescence which was visualized by fluorescent microscopy
(Figure 13) and quantified using flow cytometry (Figure 13). This induction of
fluorescence was also noted to occur in a dose dependent manner.
HCT-116 cells treated with 10 M 3PO were examined by electron
microscopy. After 24 hours of treatment, cells exposed to 3PO were noted to
have numerous intracellular structures consistent with autophagosomes (Figure
14).
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Figure 12. Markers of autophagy, LC3-II and p62, are altered by 3PO. HCT116 cells were treated with either vehicle, or 7.5, 10, or 15 M 3PO for 24 hours.
Addition of bafilomycin A1 (Baf A1) was used to determine if the changes in LC3II were the result of increased synthesis or impaired degradation. Quantitative
densitometry was conducted and protein expression was determined relative to β
actin and to control. (LC3-II quantitation is relative to control + bafilomycin due to
the absence of a visible band in the control sample). Data are presented as the
mean fold change + SD from three experiments. (p value < 0.05)
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Figure 12.
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Figure 13: 3PO increases acridine orange immunofluorescence.

HCT-

116 cells were treated with either vehicle or 7.5, 10, or 15 M 3PO. 24 hours
after treatment, cells were stained with 1ug/ml acridine orange for 15 minutes
and then viewed using a fluorescent microscope. Representative images were
captured (Figure 12A). Cells were then harvested for flow cytometry. Gating
was used to quantitate the number of cells with a high AO fluorescence and
expressed relative to vehicle (Figure 12B, C). Data are presented as the mean
relative percentages + SD from three experiments. (p value < 0.05)
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Figure 13.

M 3PO
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Figure 14: Inhibition of PFKFB3 results in autophagic structures visualized
by electron microscopy. HCT-116 cells treated with 10 M 3PO were
harvested after 24 hours and prepared for electron microscopy. Representative
images were captured. Autophagic structures were seen in cells exposed to
3PO (arrow).
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Figure 14.
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mTOR inhibition following 3PO treatment does not correlate with AMPK
Protein lysates prepared from HCT-116 cells treated with 3PO (10 M)
were examined for protein expression and phosphorylation of downstream
mTOR effectors p70S6K and S6. The levels of phosphorylated p70S6K and S6
were decreased after treatment with 3PO, indicating mTOR inhibition similar to
that seen with knockdown of PFKFB3. However, unlike the knockdown, 3PO did
not result in the activation of AMPK (Figure 15).

The lack of AMPK activation

was appropriate, however, because ATP was not found to decrease until 24
hours after treatment (Figure 16).
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Figure 15: 3PO treatment results in decreased expression of downstream
mTOR effectors. HCT-116 cells were treated with 10 M 3PO and harvested at
specified times for protein lysates.

Immunoblotting was performed using

antibodies to detect pAMPK, AMPK, p-p70S6K, p70S6K, pS6, S6, β actin and
LC3. Quantitative densitometry was used to determine protein expression and is
expressed as phosphorylated relative to total levels for AMPK, p70S6K and S6
and relative to β actin for LC3-II. All values are expressed as fold change relative
to control and are presented as the mean fold change + SD of three experiments.
(p value < 0.05)
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Figure 15.

-
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Figure 16: ATP levels are decreased by treatment with 3PO. Cells treated
with 10 M 3PO were harvested at specified times and intracellular ATP was
measured using a bioluminescence assay. ATP levels are expressed as mean
nmol ATP/ug protein relative to control + SD from three experiments. (p value <
0.05)
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Figure 16.
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PFKFB3 inhibition with 3PO increases oxidative stress
Glucose starvation is known to induce oxidative stress [124, 125]. After
determining that 3PO reduced fructose 2,6 bisphosphate and glucose uptake
very soon after treatment, we sought to determine the effect of 3PO on oxidative
stress, focusing on glutathione levels and reactive oxygen species. HCT-116
cells were treated with 10 M 3PO and harvested for glutathione measurement
using a luminescence-based assay.

After 2 hours of treatment, 3PO-treated

cells had a ~40% decrease in glutathione relative to control (p value < 0.05)
(Figure 17).
reactive

To determine if this prompt change in glutathione had an impact on

oxygen

species,

a

flow

cytometry

approach

was

employed.

Fluorescence of 2’,7’ –dichlorofluorescein diacetate (DCFDA), a dye that is used
to measure hydroxyl, peroxyl and other reactive oxygen species was determined
by flow cytometry. Reactive oxygen species were increased by more than 50%
in 3PO-treated cells (p value < 0.05) (Figure 18).
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Figure 17: 3PO treatment causes a reduction in glutathione. Glutathione
was measured using a luminescence-based assay in HCT-116 cells treated with
either vehicle or 10 M 3PO. Glutathione was calculated as g GSH/ g protein
relative to vehicle treated cells and is expressed as the mean + SD from three
experiments. (p value < 0.05)
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Figure 17.
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Figure 18: Reactive oxygen species are increased by treatment with 3PO.
HCT-116 cells treated with either vehicle or 10 M 3PO were harvested at
specified time points and loaded with 2’,7’-dichlorofluorescein diacetate (DCFDA)
for determination of reactive oxygen species by flow cytometry.

Average

geometric mean of fluorescence intensity calculated as the relative mean + SD
from three experiments is presented. (p value < 0.05)
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Figure 18.

69

Activation of autophagy due to PFKFB3 inhibition is rescued with NAC
The correlation between oxidative stress and autophagy was further
examined using the anti-oxidant N-acetylcysteine, which can act as a precursor
to the antioxidant glutathione. The drop in glutathione after 10 M 3PO treatment
was partially rescued by the addition of 1mM N-acetylcysteine (Figure 19). Nacetylcysteine also partially blocked the increase in reactive oxygen species
induced by 3PO, as determined by flow cytometric measurement of DCFDA
fluorescence (Figure 20).

This rescue of glutathione and reduction in ROS

following 3PO treatment in combination with NAC also blocked the induction of
autophagy as measured by loss of LC3-II (Figure 21) and a reduction in acridine
orange immunofluorescence (Figure 22).
N-acetylcysteine also rescued HCT-116 cells from cell death due to
treatment with 3PO. Flow cytometric analysis of cell death using Annexin V and
Propidium Iodide staining revealed a marked reduction in both early and late
apoptotic events when 1mM NAC was combined with 10 M 3PO (Figure 23).
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Figure 19: N-acetylcysteine prevents 3PO induced reduction in glutathione
levels. HCT-116 cells were treated with either vehicle or 10 M 3PO + 1mM
NAC and harvested after eight hours of treatment for measurement of glutathione
levels using a luminescence-based assay. Glutathione values were calculated
as g GSH/ g protein relative to control + NAC and are expressed as the mean
+ SD from three experiments.
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Figure 20: Reactive oxygen species production by 3PO is rescued by Nacetylcysteine. 2’,7’-dichlorofluorescein diacetate (DCFDA) fluorescence was
measured using flow cytometry in HCT-116 cells treated for eight hours with
either vehicle or 10M 3PO + 1mM NAC.

Average geometric mean was

calculated relative to control and is expressed as the relative mean + SD from
three experiments. (p value < 0.05)
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Figure 20.
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Figure 21: LC3-II induction by 3PO is blocked by N-acetylcysteine. After
eight hours of treatment with either vehicle or 10 M 3PO + 1mM NAC, cell
lysates were prepared and LC3-II levels were determined using immunoblotting.
Quantitative densitometry was performed and expressed as the fold change
relative to β actin and to control + SD. (p value < 0.05)
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Figure 21.
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Figure 22: 3PO-induced acridine orange immunofluorescence is blocked by
N-acetylcysteine. After 24 hours of treatment with either vehicle or 10 M 3PO
+ NAC, HCT-116 cells were stained with 1ug/ml acridine orange for 15 minutes.
Fluorescence microscopy was used to capture representative images (Figure
22B).

Cells were then harvested and acridine orange fluorescence was

determined using flow cytometry.

Fluorescence intensity was calculated as

average relative to control + SD (Figure 22A). (p value < 0.05)
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Figure 22.
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Figure 23: N-acetylcysteine rescues cells from death after treatment with
3PO. Cell death was measured in HCT-116 cells treated with either vehicle or 10
M 3PO + 1mM NAC. Annexin-V and PI stained cells were collected using flow
cytometry (Figure 23A).

The percentage of cells with either annexin-V only

staining or annexin-V/PI staining were determined and expressed as a
percentage relative to control + SD from three experiments (Figure 23B, C). (p
value < 0.05)
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Figure 23.
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Discussion

The observation that PFKFB3 is overexpressed in neoplastic relative to
normal tissues prompted the concept that targeting PFKFB3 expression may be
a useful anti-cancer approach. Genetic manipulation is commonly used as a
starting point to understand the importance of specific genes and proteins.
Knockdown of PFKFB3 using gene silencing resulted in enzyme inhibition.
However, as presented in Chapter II of this dissertation, knockdown of PFKFB3
also led to increased autophagic flux, presumably as a resistance mechanism to
the knockdown. To expand these findings in a way that is more relevant and
applicable to treating human disease, a drug-based approach was employed.
A drug that had previously been shown to inhibit PFKFB3, 3PO, was used
to treat HCT-116 cells. Similar to PFKFB3 knockdown, PFKFB3 inhibition using
3PO reduced glucose uptake as well as reduced the levels of F2,6BP in this
model system. Corresponding to the changes seen after PFKFB3 knockdown,
inhibition with 3PO also resulted in increased autophagic flux, as measured using
protein markers, acridine orange staining and electron microscopy.
Knockdown of PFKFB3 resulted in decreased ATP levels and an increase
in AMPK activation as measured by phosphorylation. Since knockdown usually
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results in a gradual change in protein expression and drug treatment has a more
immediate effect it was not surprising that 3PO did not seem to activate AMPK as
was seen with PFKFB3 knockdown. In fact, ATP levels did not even begin to
decrease after 3PO treatment until at least 24 hours.

Still, phosphorylated

protein markers downstream of mTOR, phospho-p70S6K and phosphoribosomal protein S6 were found to be decreased even in the absence of AMPK
activation. This indicated that for the acute response, an alternative mechanism
was involved in mTOR suppression and autophagy activation.

Autophagy

induction, even that induced by metabolic stress, has been shown to occur
independently of ATP and AMPK as the result of other stimuli such as
endoplasmic reticulum (ER) stress or through SIRT1/FOX01/3 [126-128].
Additionally, starvation can result in decreased glutathione and the accumulation
of reactive oxygen species [125, 129], and this oxidative stress is another
stimulus for autophagic induction which can serve as a survival mechanism,
mitigating damage by degrading oxidized proteins and by degrading damaged
mitochondria [36-38, 130-138] There is abundant evidence that oxidative stressinduced autophagy occurs through inhibition of the mTOR pathway [125, 131,
139-142].
Oxidative stress is recognized as a potent activator of autophagy and can
also be increased under stressful stimuli such as glucose starvation [125, 141,
143]. Nutrient deprivation can lead to oxidative stress due to the accumulation of
reactive oxygen species (ROS). ROS, reactive molecules that contain oxygen,
are produced as a byproduct of normal cellular metabolism, are present at low

82

levels in all cells, serving as signaling molecules [144] and playing a role in
immune function [145, 146].

However, when improperly regulated, ROS can

cause damage to intracellular macromolecules and organelles [147] . The main
defense against ROS is the action of anti-oxidants, including catalases,
superoxide dismutases, and glutathione. Glutathione (GSH), a tripeptide formed
by glycine, cysteine and glutamate, is the most abundant intracellular non-protein
thiol and plays a critical role in limiting oxidative damage by scavenging ROS.
Glutamylcysteine synthetase initiates the formation of GSH by catalyzing an
amide linkage between glutamate and cysteine. Glycine is then added by GSH
synthetase to complete the formation of GSH. Donation of electrons to ROS
leads to the formation of an oxidized thiol radical (GS) which can then form a
disulfide bond with another thiol radical to form GSSG. Accumulation of GSSG
can be toxic and normally accounts for about 1% of the total cellular glutathione
[148] GSSG can be converted back to GSH by glutathione reductase, which
requires reduced nicotinamide adenine dinucleotide phosphate (NADPH) as an
electron donor. GSSG can also be transported across the plasma membrane as
a way to prevent accumulation [149]. GSH may also have ROS-independent
protective effects on cell function, some of which may be due to its function in
glutathionylation [150-152]. Data presented here indicate that 3PO treatment
results in a rapid decline in GSH as well as ROS accumulation.
Autophagic induction by 3PO seems to depend on oxidative stress, as
supported by rescue using N-acetylcysteine. N-acetylcysteine, a compound with
a reactive thiol group capable of reducing free radicals and a precursor to
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glutathione, rescues not only the oxidative stress caused by 3PO, seen as a
return in GSH and ROS levels towards that seen with vehicle treatment, but also
prevents autophagic induction. At this time, the mechanism by which 3PO leads
to an increase in oxidative stress, whether by increasing ROS which results in
depletion of GSH, or by first causing depletion in the GSH pool resulting in the
accumulation in ROS, is unclear. However, the induction of autophagy by the
PFKFB3 inhibitor 3PO does appear to depend on oxidative stress and there is
evidence that it may be through inhibition of mTOR, a pathway noted to be
involved in autophagic induction by oxidative stress [153, 154]. While 3PO has
mostly cytostatic effects at low doses, cytotoxicity is observed at high doses or
after long periods of exposure. This cytotoxicity is almost completely abrogated
upon the addition of NAC suggesting that inducing oxidative stress is a
mechanism by with 3PO can result in cell death. However, the larger percentage
of cells that survive treatment with 3PO suggests that these cells could be
responding to the oxidative stress in order to prevent cell death. Autophagy is a
well-known defense against oxidative stress [138, 155].

Thus, inhibiting

autophagy in the setting of 3PO treatment could shift this resistant population
towards cell death.
Although through two distinct biochemical mechanisms, autophagy was
induced by both the knockdown of PFKFB3 using siRNA and by enzyme
inhibition using 3PO.

The interest in PFKFB3 inhibitors as a new cancer

treatment option means that recognition of potential drug resistance mechanisms
may lead to more successful combinations when resistance in encountered.
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Autophagy is now a widely recognized process induced by stimuli such as
nutrient deprivation or chemotherapeutic drugs.

However, there is some

disagreement as to the function of autophagy as a tumor suppressive versus as
a tumor survival mechanism. In support of a tumor suppressive mechanism, the
mammalian orthologue of yeast Atg6, Beclin1, is deleted in large number of
human cancers including breast, ovarian and prostate cancers [156].
regard, autophagy is theorized to reduce genomic instability.

In this

Loss of this

process, by deletion of Beclin1, results in tumorigenesis due to increased
genomic instability. Additionally, autophagy has been seen to prevent necrotic
inflammation which prevents the release of tumor promoting cytokines [90] and
the persistent activation of autophagy can eventually lead to death via a
caspase-independent mechanism [157]. The oncogenic regulation of autophagy
is

also

not

entirely

clear.

Some

tumor

suppressors

(e.g.

PTEN)

activate autophagy, and some oncogenes can inhibit autophagy (Akt, Ras, ERK)
while others, such as p53, have been shown to both activate and inhibit
depending on the context [158-162].

Still, despite these indications that

autophagy may suppress tumor initiation or growth, there is more evidence that
autophagy is actually a tumor survival mechanism.

In order to metastasize,

tumor cells must overcome matrix detachment-induced cell death, anoikis.
Autophagy has been shown to be protective against cell death during this
process which may function in facilitating metastatic spread [163]. Autophagy
can also serve to promote survival of dormant tumor cells which could have
major implications for adjuvant therapies aimed at preventing recurrence. [164,
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165]. This role of autophagy in dormancy is the result of reduced proliferation,
the same function that is also touted as a tumor suppressive function. However,
the function to reduce proliferation until adequate nutrients or a more conducive
environment are encountered is surely one that can be viewed as tumorigenic
rather than suppressive. Additionally, there is now considerable evidence that
the combination of inhibitors of autophagy with drugs that induce autophagy in
cancer cells can increase tumor cell death [77, 158, 166-168]
The most currently accepted model of autophagy is that of a process with
a dual nature, depending on tumor type and stage. Autophagy may suppress
tumor initiation via reduced genomic instability and prevention of chronic
inflammation and necrosis, while later serving as a cell survival mechanism by
allowing stress tolerance through increased production of metabolic precursors,
mitigating excessive damage that can be caused by damaged mitochondria, and
facilitating metastasis by protecting from anoikis-induced cell death.
To determine if the autophagy induced by knockdown or inhibition of
PFKFB3 could be exploited to increase efficacy as an anti-tumor agent, the next
step was to evaluate how tumor cells reacted to the combination of PFKFB3
inhibition and autophagy inhibition both in vitro and in vivo.
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CHAPTER IV
INHIBITION OF PFKFB3 HAS ADDITIVE ANTI-TUMOR
EFFECTS WITH PHARMACOLOGIC AUTOPHAGY
INHIBITORS

Introduction

While there was an indication of cytotoxic activity of 3PO in transformed
cells, this toxicity occurred at concentrations that also had toxic effects on
untransformed cells.

At lower concentrations, when the drug was found to

influence transformed cells more than normal cells, the effect was more
cytostatic [53]. In vivo tumor experiments using 3PO resulted in a significant
reduction in tumor growth relative to vehicle treated animals. However, tumors in
animals treated with 3PO, while smaller than the controls, continued to grow
through drug treatment. Like most drugs currently used to treat human cancers,
3PO seemed to have restricted efficacy as a single drug option, making rational
drug combination an important step to ensure maximal efficacy when used to
treat human cancer patients.
The majority of cancers not amenable to surgical removal are treated with
combinations of chemotherapeutic drugs. It is well known that neoplastic cells
are capable of evading and resisting treatment making the recognition of
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resistance

mechanisms

imperative

to

the

identification

combinations of drugs to counter such defenses.
mechanisms

employed

by

tumor

cells

to

of

successful

There are numerous

avoid

death

caused

by

chemotherapeutic agents. In some tumors, cells have membrane protein pumps
that prevent drug from accumulating inside [149, 169].

Other mechanisms

involve changes that reduce the sensitivity to drug-induced apoptosis, allowing
for survival even in the presence of pro-apoptotic signals [170]. Another way that
tumor cells resist destruction is through the activation of autophagy, a ubiquitous
intracellular catabolic processing pathway [41-44].

An increase in autophagic

processing results in the degradation of intracellular proteins and organelles for
the production of biosynthetic precursors can be used to fuel the continued
production of ATP and lead to cell survival under adverse conditions. Autophagy
is now recognized as a major resistance mechanism of tumors to a large number
of drug therapies [50-52, 55, 57, 78]. The cause for increased autophagic flux is
not always identified but, nonetheless, can be taken advantage of by the addition
of autophagy inhibitors to therapy regimens.
The increased detection of autophagy due to drug treatment in cancer has
resulted in great interest in the use of autophagy inhibitors in cancer therapy.
While there are now a number of drugs known to inhibit autophagy, the drug that
is currently the most widely used for this purpose is chloroquine, a drug that was
originally developed as an anti-malarial agent.
Chloroquine is a 4-aminoquinoline drug that has been used to treat
malaria for more than half a century. The original observation that malaria could
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be treated using the bark of cinchona trees led to the isolation of quinine. The
molecular structure of quinine was determined and later, a derivative with potent
anti-malarial activity called Resochin, N’-(7-chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine, and later renamed chloroquine, was produced [171, 172].
Chloroquine in an unprotonated form can diffuse across membrane bilayers.
However, once protonated in the lysosome, chloroquine is no longer able to exit
and accumulates resulting in the inhibition of lysosomal enzymes such as
phospholipase A2, lysophospholipid acylhydrolase [173, 174].

This inhibition

blocks the final step of autophagy, degradation on autophagosomal contents by
lysosomal enzymes.

Chloroquine was later shown to be effective in treating

other diseases such as rheumatoid arthritis and HIV [175-177]. The observation
of a reduced incidence of Burkitt’s lymphoma in malaria patients treated with
chloroquine was made in 1989 [178].

More recently, chloroquine has been

shown to reduce autophagy in vivo and to potentiate the anti-cancer effects of
some cancer therapies [55, 167, 179, 180]. The relatively mild safety profile and
widely accepted use of chloroquine makes this compound attractive for use in a
combination drug trial for cancer. As such, chloroquine is currently being used in
combination with a number of other agents as part of clinical trials, including
carmustine, paclitacel, gefitinib, and temozolomide among others reviewed in
[181].
To determine the effect of autophagy inhibition in combination with
PFKFB3 inhibition in transformed cells, HCT-116 cells were treated with
combinations of PFKFB3 inhibitors and autophagy inhibitors and cell death was
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measured. The addition of autophagy inhibitors to PFKFB3 inhibitors resulted in
more cell death than either inhibitor alone.

While these results were

encouraging, in vitro assays do not always accurately predict the effects of
certain treatments when used in vivo. This can be due to a number of factors
including the tumor microenvironment, such as access to blood supply and
nutrients, or to the heterogeneous nature of tumors.

Additionally, systemic

effects such as drug metabolism or activation/inactivation and unexpected
toxicities are impossible to predict using an in vitro modeling system.

As

predicted, tumors from animals treated with the combination of 3PO and
chloroquine grew significantly slower relative to animals treated with either drug
alone. While a significant amount of work needs to be done before these results
can translate into an effective treatment option for human cancer patients, data
here support the increased efficacy of PFKFB3 inhibitors when combined with
inhibitors of autophagy.
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Materials and Methods

Cell Culture
Human colorectal carcinoma cells (HCT116) were cultured as described in
Chapter II.

Lewis lung carcinoma cells (LLC) obtained from American Type

Culture Collection (Manassas, VA) were cultured in Dulbecco’s Modified Eagle
Medium (Gibco, Grand Island, NY) supplemented with 10% calf serum and
50ug/mL gentamicin. Cells were incubated at 37 C with 5% CO2.

Drug Treatment
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one

(3PO),

PF15,

PF158

(Advanced Cancer Therapeutics, Louisville, KY). Chloroquine, 3-methyladenine,
Spautin-1, Bafilomycin A1 from (Sigma, St. Louis, MO).

Samples in which

bafilomycin A1 was used were treated with 1nM bafilomycin A1 24 hours prior to
harvest.

Protein Extraction and Immunoblotting
Protein extraction and immunoblotting were performed as described in
Chapter II.
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Acridine Orange Immunofluorescence
Acridine orange staining and immunofluorescence measurements were
performed as described in Chapter II.

Flow Cytometry for Cell Death
Cell death was assessed using method described in Chapter II.

Tumor model system
12 week old female C57/BL6 mice were injected subcutaneously with
1x106 Lewis lung carcinoma (LLC) cells and once tumors reached 150-200 mg,
mice were randomized into four groups (N=6 per group): Group 1: Vehicle
(DMSO+PBS), Group 2: Chloroquine (DMSO+50mg/kg CQ), Group 3: 3PO
(0.07mg/g 3PO+PBS), Group 4: (0.07mg/g 3PO+50mg/kg CQ). Drug treatments
were based on published tumor models [53, 167, 182]. Mice were given two
daily intraperitoneal injections with either vehicle or drug and tumors were
measured using calipers for estimation of tumor volume. At the conclusion of the
study, mice were euthanized and tumors were removed. Tumors tissues were
fixed in paraformaldehyde and prepared for immunohistochemistry.
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Immunohistochemistry
Tumors excised after completion of all tumor measurements were fixed in
paraformaldehyde for 24 hours and then embedded in paraffin, sections and
stained

with

anti-cleaved

caspase

immunohistochemical methods.
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3

antibody

using

standard

Results

Pharmacologic inhibition of autophagy in combination with 3PO increases
tumor cell death
To determine if autophagy following 3PO treatment serves as a survival
mechanism, chloroquine, an agent that accumulates in lysosomes and interferes
with autophagy was used in combination with 3PO. Treatment of HCT-116 cells
with 15 or 30 M chloroquine led to a dose-dependent increase in cell death
when combined with 3PO treatment as measured by flow cytometric analysis of
annexin V and propidium iodide staining (Figure 24).
Two additional inhibitors of autophagy were also used in combination with
3PO to look for increased cell death, 3-methyladenine and Spautin-1.

3-

methyladenine (3MA), an inhibitor of type III phosphatidylinositol 3-kinases,
which blocks the formation of autophagosomes was used to treat HCT-116 cells
(1mM) that were also treated with either vehicle, or 3PO.

Cell death was

assessed using annexin V and PI staining and quantified by flow cytometry. The
number of cells staining positive for both annexin V and PI was increased in
samples treated with the combination of 3MA and 3PO relative to either drug
alone (Figure 25). Spautin-1, which inhibits autophagy by promoting increased
proteasomal degradation of class III PI3 kinase complexes through inhibition of
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ubiquitin-specific peptidases USP10 and USP13 also resulted in greater numbers
of annexin-V and PI double positive cells when used in combination with 3PO
(Figure 26).
To assess whether the combined effects of autophagy inhibitors and the
PFKFB3 inhibitor was limited only to the specific inhibitor 3PO, two other
derivatives of 3PO were used to treat cells in combination with the autophagy
inhibitor chloroquine.

Cell death, assessed using flow cytometry measuring

annexin V and PI staining, was increased when chloroquine was combined with
3PO derivative PF-158 (Figure 27) or derivative PF-15 (Figure 28).
This increase in cell death upon the addition of chloroquine was also
noted in HCT-116 cells that had been transfected with a siRNA directed against
PFKFB3 (Figure 29).
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Figure 24: Synergistic increase in cell death when 3PO is combined with
the autophagy inhibitor chloroquine. Annexin-V/PI staining was performed in
cells treated with vehicle, 3PO, chloroquine, or the combination of 3PO and
chloroquine for 48 hours. Quantitation of cell staining was performed using flow
cytometry (Figure 24A) and the number of cells staining with both annexin-V and
PI was quantitated and is expressed as the percentage relative to control + SD
from three experiments (Figure 24 B). (p value < 0.05)
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Figure 24.
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Figure 25: The autophagy inhibitor, 3-methyladenine, increased cell death
when combined with 3PO. HCT-116 cells were treated with either vehicle or
7.5 M or 10 M 3PO + 1mM 3-methyladenine (3MA). 24 and 48 hours after
treatment cells were stained with annexin-V and PI and measured using flow
cytometry (Figure 25A). Cell death was quantitated as the percentage of cells
staining positive for annexin-V and PI relative to control + SD from three
experiments (Figure 25B). (p value < 0.05)
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Figure 25.
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Figure 26. The combination of Spautin-1 and 3PO increased cell death.
HCT-116 cells were treated with either vehicle, 7.5 or 10 M 3PO + 15 M
Spautin-1. After 24 or 48 hours of treatment cells were stained with annexin-V
and PI and collected by flow cytometry (Figure 26A). The percentage of cells
stained positive for both annexin-V and PI was quantitated and is expressed
relative to control + SD from three experiments (Figure 26B). (p value < 0.05)
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Figure 26.
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Figure 27. The 3PO derivative PF158 causes increased cell death when
combined with chloroquine.

HCT-116 cells treated with vehicle or 0.5 M

PF158 + 30 M CQ were stained with annexin-V and PI and collected by flow
cytometry (Figure 27A).

Annexin-V/PI positive cells were quantitated as

percentage of total relative to control + SD from three experiments (Figure 27B).
(p value < 0.05)
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Figure 27.
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Figure 28. Cell death by PF-15, a derivative of 3PO, is increased when
combined with chloroquine. After treatment with either vehicle or 1M PF-15 +
30 M chloroquine, HCT-116 cells were stained with annexin-V and PI and
collected by flow cytometry (Figure 28A) (Figure 28A). Cells staining positive for
annexin-V and PI were quantitated as percentage of total relative to control
presented as mean + SD from three experiments (Figure 28B). (p value < 0.05)

104

Figure 28.
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Figure 29: Cell death due to knockdown of PFKFB3 is increased when
combined with the autophagy inhibitor chloroquine.

HCT-116 cells were

transfected with either a negative control siRNA or with a PFKFB3-specific siRNA
+ 30 M CQ. After 48 hours of transfection, cells were stained with annexin-V
and PI and measured using flow cytometry (Figure 29A). Quantitation of cells
staining positive for annexin-V and PI was performed relative to control and is
expressed as the mean + SD from three experiments (Figure 29B). (p value <
0.05)
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Figure 29.
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Validation of a mouse tumor cell line prior to in vivo experiment
Before moving to an in vivo model, a mouse tumor cell line, Lewis lung
carcinoma (LLC) was evaluated for autophagy and increased sensitivity to
chloroquine following treatment with 3PO.

Lewis lung carcinoma cells treated

with 10 M 3PO had increased levels of LC3-II relative to control. This increase
was further enhanced upon the addition of bafilomycin A1 (Figure 30). Acridine
orange immunofluorescence was also increased by 10M 3PO in LLC cells as
determined visually by fluorescence microscopy (Figure 31 A), and quantified by
flow cytometry (Figure 31B). Similar to the HCT-116 cells, Lewis lung carcinoma
cell death was also increased when chloroquine treatment was used in
combination to 3PO treatment relative to either drug alone (Figure 32).
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Figure 30: Autophagic protein marker LC3-II is increased in Lewis lung
carcinoma cells exposed to 3PO. LLC cells were treated with 25 M 3PO for
24 hours. LC3-II levels were measured using immunoblotting and quantitative
densitometry was performed. Levels expressed as mean fold change LC3-II/β
actin relative to control + SD (Figure 30B). (p value < 0.05)
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Figure 30.
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Figure 31: Lewis lung carcinoma cells treated with 3PO have increased
acridine orange staining. LLC cells treated with 25 M 3PO for 24 hours were
stained with acridine orange. Cells were viewed by fluorescent microscopy and
representative images were taken (Figure 31A). Flow cytometry was performed
and the relative number of cells with a high level of acridine orange staining was
quantitated and is expressed as the mean + SD from three experiments (Figure
31B). (p value < 0.05)
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Figure 31.
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Figure 32: The combination of 3PO and chloroquine has synergistic effects
on cell death in Lewis lung carcinoma cells. LLC cells were treated with
either vehicle or 10 M 3PO + either 15 or 30 M CQ.

After 24 hours of

treatment cells were stained with annexin-V and PI and measured using flow
cytometry (Figure 32A). Cells staining positive for both annexin-V and PI were
quantitated as the percentage of the total relative to control and data is presented
as the mean + SD from three experiments (Figure 32B). (p value < 0.05)
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Combination of autophagy inhibition and 3PO decreases tumor growth in
vivo
12 week old female C57/BL6 mice were used to determine the in vivo
effect of the combination of chloroquine and 3PO on tumor growth. Animals
were injected subcutaneously with 1x106 Lewis lung carcinoma cells.

When

tumors reached 150-200 mm3, calculated based on volume, mice were
randomized into four treatment groups (N=6 per group).

Group 1: Vehicle

(DMSO+PBS), Group 2: Chloroquine (DMSO+50mg/kg CQ), Group 3: 3PO
(0.07mg/g 3PO+PBS), Group 4: (0.07mg/g 3PO+50mg/kg CQ).

Daily tumor

measurements were obtained using calipers for estimation of tumor mass. The
experiment was concluded two weeks from the start of drug treatment and
tumors were collected for further examination. The tumor mass was significantly
reduced in animals treated with both 3PO and chloroquine relative to either drug
treatment alone (Figure 33).
immunohistochemistry.

Excised tumors were fixed and prepared for

The tumor sections were stained with an antibody

recognizing cleaved caspase-3, a key protein in the execution phase of
apoptosis.

Tumors from animals treated with the combination of 3PO and

chloroquine were noted to have an increased number of cleaved caspase-3
positive cells relative to tumors from animals treated with either drug alone
(Figure 34).
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Figure 33: Combination therapy using 3PO and chloroquine reduces tumor
growth in a Lewis lung carcinoma tumor model in vivo. C57/BL6 mice were
inoculated with 1x106 Lewis lung carcinoma cells by subcutaneous flank
injection. Mice were randomized into 4 treatment groups when tumors reached
150-200 mm3 and were treated by i.p. injections with either vehicle, 50mg/kg
chloroquine, 0.07mg/g 3PO, or a combination of the two drugs.

Tumor

measurements taken over the course of treatment were used to calculate tumor
mass. Data is presented as mean tumor mass + SD. (p value < 0.05)
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Figure 33.
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Figure 34: Immunohistochemistry of excised tumors from 3PO +
chloroquine treated animals have increased cleaved-caspase 3 staining.
Tumors were fixed, paraffin embedded and stained with an antibody directed
against cleaved caspase-3 (CC3). The number of cells staining positive for CC3
was in a 200X field was counted and data is expressed as the mean + SD from
three counts. (p value < 0.05)
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Figure 34.
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Discussion

The increasing identification of autophagy as a resistance mechanism
utilized by tumor cells to avoid destruction led to postulation of improved antitumor effects by the combination of autophagy inhibitors with PFKFB3 inhibitors.
We have shown that cell death following treatment with PFKFB3 inhibitor 3PO
was increased when combined with autophagy inhibitors chloroquine, 3methyladeneine or Spautin-1.

Additionally, chloroquine increased cell death

when combined with other derivatives of the PFKFB3 inhibitor 3PO, PF-158 and
PF-15, showing that the combination of chloroquine is not limited to only one
PFKFB3 inhibitor. While these inhibitors, 3PO, PF-158 and PF-15, have been
shown to inhibit PFKFB3 enzyme activity, these compounds most certainly have
some off-target effects.

For this reason, chloroquine was also tested in

combination with PFKFB3 siRNA and enhanced cell death was noted. These
observations support the role of autophagy as a resistance mechanism following
the inhibition of PFKFB3 activity.
While in vitro research is absolutely essential to the understanding of cell
function, data collected is limited by unforeseen effects that occur only in vivo.
Animal studies are laborious, costly, and, even more importantly, result in the
expenditure of numerous animal lives. Once sufficient data has been compiled
from in vitro work, it is necessary and responsible to expand studies to an animal
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model system in order to increase its relevance. This is especially important
when evaluating drugs or combinations of drugs due to unanticipated systemic
effects that can occur.
Chloroquine has been safely used as an anti-malarial agent since the
1940’s and has more recently been used as an anti-tumor agent. Based on
previously reported animal tumor studies using chloroquine, a dose of 50mg/kg
was selected [36, 54, 183, 184]. The dose of 3PO used for this study (0.07mg/g)
was also selected based on a previously published animal tumor model [53].
The combination of 3PO and chloroquine resulted in significantly smaller tumors
relative to either drug treatment alone. While there was a substantial difference
in tumor size, it is important to note that 3PO treatment alone did not have the
same anti-tumor effects that were seen in the previously published work [53],
although the tumor model (Lewis lung carcinoma tumors in C57/BL6 mice) was
the same. Additionally, although the model system was different, tumors from
animals treated with chloroquine alone failed to show any difference in tumor
size, contrasting with other published tumor studies [183, 184]. While this may
be due to the use of slower growing tumor models that are not as sensitive to
chloroquine the LLC tumors grew very quickly, with the first tumors palpable
merely three days after inoculation. Drug treatment was started when tumors
reached between 150-200 mm3, calculated based on caliper measurements,
which was less than one week after inoculation for most animals, in contrast to
two to four weeks between inoculation and drug treatment in other models [183,
184]. In fact, in those studies it was not until more than three weeks after tumor
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inoculation that the average tumor mass in chloroquine-treated animals was
smaller than the vehicle treated, which is longer than the length of the entire
study presented here [184]. In this setting it is reasonable to speculate that the
drugs may have had a difficult time competing with the accelerated growth of
tumors. Future studies may benefit from using a slower growing model system so
that treatment time can be extended.
Tumors that were removed from animals at the conclusion of the study
were fixed and stained with a marker of cell death, cleaved-caspase 3. This
marker was increased in tumors excised from animals treated with the
combination of chloroquine and 3PO relative to those from animals treated with
either drug alone. The smaller tumor size and increased CC3 staining supports
the idea that autophagy is serving as a protective mechanism following PFKFB3
inhibition and that the efficacy of PFKFB3 inhibitors as anti-cancer agents may
be improved using autophagy inhibitors such as chloroquine.
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Figure 35. Inhibition of glycolysis causes induction of autophagy for
survival.

Metabolic stress due to PFKFB3 knockdown results in AMPK

activation

and

subsequent

mTOR

inhibition

which

relieves

autophagy

suppression allowing for increased cell survival. PFKFB3 inhibition using 3PO
results in a much more rapid inhibition of glycolysis resulting in acute oxidative
changes that lead to mTOR inhibition and autophagy induction.

Adding

chloroquine, an autophagy inhibitor, to either knockdown or to 3PO increases cell
death.
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Figure 35.
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CHAPTER V

SUMMARY

Harnessing our knowledge gained from studying cancer cells over the
past century in order to determine the traits that distinguish them from normal
cells is paramount to developing cancer-specific therapies.

Inhibition of 6-

phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) has proven to
effectively and specifically target tumor cells in vitro and to decrease tumor
burden in vivo [53].

Clinical trials using PFKFB3 inhibitors are forthcoming.

However, like so many chemotherapeutics, it is not unexpected that resistance to
these inhibitors could be encountered in the setting of human cancers.
Resistance is often battled using combinations of drugs, which have now become
standard, making single drug therapies quite rare.

Elucidating the specific

resistance mechanisms triggered by chemotherapeutic drugs allows for the
selection of combinations that might work to combat such resistance with the
hope of increasing efficacy. In this work we show that autophagy is induced by
PFKFB3 inhibition and that this induction is likely serving as a resistance
mechanism as supported by the observations of increased cell death in vitro and
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slowed tumor growth in vivo when combined with pharmacologic inhibitors of
autophagy. It is likely that the use of drugs targeting PFKFB3 in human cancers
will benefit from combinatorial therapies, such as that supported here with the
autophagy inhibitor chloroquine.
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FUTURE DIRECTIONS

EXPANSION OF MODELING SYSTEMS
Like Galileo’s heliocentric model of the universe, Warburg’s theory
regarding tumor cell metabolism, while still a major contribution to our
understanding of tumor cell metabolism, may be flawed. He originally proposed
that cancer cells utilized glycolysis due to damaged mitochondria preventing
efficient oxidative respiration [2]. It is now thought that mitochondrial defects are
somewhat rare and that most tumor cells not only have the capacity for but also
utilize oxidative metabolism, albeit at reduced rates [185]. Still, it is clear that the
increased uptake and utilization of glucose is a distinguishing attribute of tumor
cells relative to normal cells, a feature that is taken advantage of for visualizing
tumors by PET scanning using 2-deoxy-2-(18F)fluoro-D-glucose positron
emission tomography (FDG-PET) imaging.
To account for the increased uptake in glucose of tumors despite
functional mitochondrial an alternative hypothesis, termed the “Reverse Warburg
Effect” was proposed [186]. It postulates that the increased glycolytic flux in
tumors is not due to the cancer cells themselves, but to stromal cells in the tumor
microenvironment.

In this model, oxidative stress resulting from cancer cell

release of H2O2 stimulates stromal cells to undergo autophagy, and, in particular,
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selective mitochondrial autophagy, leaving them dependent on glycolysis for
energy production [187, 188].

Thus, it is the stromal cancer-associated

fibroblasts that are responsible for increased glucose uptake and utilization.
These fibroblasts are then observed to release lactate and pyruvate as a result of
increased glycolytic flux, which is taken up as a fuel for mitochondrial respiration
in the cancer cells.

In support of this theory, cancer cells co-cultured with

fibroblasts were observed to have increased mitochondrial mass and decreased
glycolytic flux relative to cancer cells cultured alone. Additionally, fibroblasts cocultured with cancer cells had decreased mitochondrial activity [189]. Whether it
is due to stromal cells or to cancer cells or both, it is clear that tumors take up
more glucose than normal tissues.

It is reasonable to speculate that anti-

glycolytic drugs, such as PFKFB3 inhibitors, will be more effective as cytostatic
or cytotoxic agents in cells with increased glycolytic potential. For this reason it
would be important to return to the in vitro system and look at PFKFB3 inhibition
in the setting of co-cultures of tumor cells and fibroblasts to determine if one cell
type seems to be affected more than the other. In this same model system, other
consequences of PFKFB3 inhibition, such as the induction of autophagy, could
be measured to understand how cells within the tumor environment behave in.
Additionally, the work presented in this dissertation is limited by the model
system used to evaluate PFKFB3 knockdown or inhibition. Future studies will
also be conducted in multiple cell lines including a variety of tumor cells
originating from different organs as well as in normal cells derived from primary
cultures. It will also be important to study the combination of PFKFB3 inhibitors
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with more specific autophagy inhibitors. The use of chloroquine in this work was
based on its action to inhibit autophagy and its long-standing safety profile in
humans. As the autophagy field expands, it is likely that more inhibitors will be
developed that have greater specificity for the autophagic process. This could
mean that these agents are more tumor-specific and will have greater anti-tumor
effects than chloroquine. As well as expanding the variety of drugs used to inhibit
autophagy, it will be important to test newer derivatives of PFKFB3 inhibitors with
fewer off-target effects and with lower toxicity ranges.
Another limitation of the work presented here is the singular in vivo model
system. The animal study was performed using a mouse tumor cell line. More
sophisticated, and also more expensive, xenograft modeling systems that utilize
human cancer cells in an immunodeficient athymic mouse may more
appropriately simulate the effect that PFKFB3 inhibitors will have on human
cancers.

UNDERSTANDING THE ROLE FOR GLUTAMINOLYSIS
Other studies that could further our understanding of the role of PFKFB3
in cancer and the consequences of inhibition as a means to treat cancer should
be focused on glutamine metabolism. Glutamine is another substrate, in addition
to glucose, that is utilized to a greater extent in cancer cells relative to normal
cells [190, 191]. Glucose deprivation is known to induce glutaminolysis which
increases the synthesis of TCA intermediates, reduces oxidative stress by
production of NADPH, and also causes increased ammonia, a known inducer of
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autophagy [192-194]. Glutamine can also be used to make GSH. Glutaminase
converts glutamine to glutamate which can be acted upon by glutathione cysteine
ligase to be converted directly to GSH [195]. A gradual reduction in PFKFB3
using siRNA may result in the transition to utilization of glutamine as an
alternative energy source. The subsequent metabolism of glutamine could be
used to increase GSH, thus limiting reactive oxygen species. In fact, in data not
shown, PFKFB3 knockdown was observed to result in less reactive oxygen
species and in stabilization of the intracellular GSH pool. Conversely, the rapid
decline in glucose uptake resulting from PFKFB3 inhibition using 3PO may lead
to excessive reactive oxygen species that causes utilization and a decrease in
the GSH pool, occurring before the cell has the time to utilize glutamine and
counteract oxidative stress with increased GSH synthesis. Clearly it would be of
great interest to study glutaminolysis in the setting of both PFKFB3 knockdown
and PFKFB3 inhibition. As part of this endeavor,

14

C-labeled glutamine might be

used to measure glutamine uptake via scintillation counts in cells that treated
with either PFKFB3 siRNA or with pharmacologic PFKFB3 inhibitors.
Additionally, 13C-labeled glutamine could be used by nuclear magnetic resonance
studies to understand how glutamine metabolism is altered in cells in which
PFKFB3 is manipulated.

Depending on the results of these studies,

glutaminolytic modulators may be combined with PFKFB3 inhibitors to look for
synergistic effects on tumor cell proliferation and viability.
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EXPLOITING OXIDATIVE STRESS
Another combination approach that may result in more effective cancer
therapies is that of PFKFB3 inhibitors and drugs known to cause oxidative stress.
The induction of ROS by PFKFB3 inhibition, and the additive effects on tumor
cell death upon combination with chloroquine, a compound that, itself, has been
shown to increase ROS, may mean that the combinatorial effects on cell death
are due to a massive increase in ROS that tumor cells cannot battle [196]. There
are a number of examples where utilization of drugs known to increase reactive
oxygen species and oxidative stress have been successfully combined with
chemotherapeutic drugs, a topic that has previously been reviewed [197]. Thus,
it is possible that the combination of PFKFB3 inhibitors with these pro-oxidative
agents will have even greater success than the combination with chloroquine. In
fact, glucose-withdrawal induced oxidative stress has been observed to be
greater in some tumor cells relative to normal cells which could indicate
increased tumor specificity of this type of combination with PFKFB3 inhibitors
[198]
In order to gain a greater understanding of how PFKFB3 manipulation
affects oxidative stress, the source of stress must be elucidated. As previously
stated, changes in glutamine metabolism may have a role in the production of
GSH and, thus, the mitigation of damage that could be caused by ROS.
Additionally, it will be important to measure the changes in mitochondrial mass,
and function, by measuring membrane potential, oxygen consumption, and the
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production of mitochondrial-specific reactive oxygen species, after PFKFB3
manipulation.

THE HUMAN PERSPECTIVE
In vitro culture systems and in vivo animal modeling can only take us so
far in the search for a cure to cancer. To treat human cancers we need to better
understand their characteristics and functional requirements in their natural
environment. Observing that some measure of metabolism or that expression of
an activated protein in a pathway presumed to be important in cancer cells is
changed after 6, 12, or 24 hours of treatment is not as meaningful as looking at
what is happening in the majority of tumor cells at any point in time within the
human body. Perhaps even more importantly, determining how tumors, as a
whole, react to treatment with chemotherapeutics is critical to how we will move
forward to treat tumors and to modify treatments based on a tumor’s response to
treatment.

As part of this mission, it would be of great interest to examine

samples taken from a variety of human tumors and measure PFKFB3 expression
and markers of autophagy to look for correlations between glycolytic and
autophagic activity. Additionally, once PFKFB3 inhibitors enter human cancer
trials, tumor samples could be examined after treatment for assessment of
autophagy markers. Correlations between the response of particular tumors,
growth, shrinkage, or stabilization of tumor size with these autophagic markers
could be used to make therapeutic modifications, for example, the addition of
chloroquine or another inhibitor of autophagy.
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Work presented herein supports the protective role of autophagy in cancer
cells following inhibition of PFKFB3, a key enzyme involved in the regulation of
glycolysis. Treatment using PFKFB3 inhibitors and autophagy inhibitors, such as
chloroquine, have shown promise as a combinatorial approach to tumor therapy.
Still, as detailed above, a considerable amount of work needs to be
accomplished to gain a better grasp on how to effectively target tumors by
inhibiting PFKFB3. Hopefully the studies presented in this dissertation will serve
as the groundwork for the development of novel and successful cancer anticancer strategies.
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